Company intelligence / Profile preview

Healios

Chiyoda-ku, Tokyo, Japanhealios.org.uk ↗

Ownership: Private
Employees: ~60
Development stage: Commercial

Overview

Healios has advanced its lead asset, HLCM051, into late-stage clinical trials for ARDS and ischemic stroke. The company is also developing iPSC-derived natural killer cells for cancer immunotherapy and retinal therapies. It has demonstrated the ability to manufacture at scale using proprietary technologies and maintains a robust R&D pipeline with several assets in various stages of development[4][5].

Therapeutic areas: PulmonologyCardiovascularOphthalmologyOtherOncology
Modalities: Induced pluripotent stem cell derived therapyCell therapySomatic stem cell therapy
Industry: Biotech

Drug pipeline

2 assets

invimestrocel

1 more asset in the full pipeline.

Request access →

Partnerships

Sumitomo Pharma Co., Ltd. (joint venture Sighregen Co., Ltd.)Athersys Inc. (technology acquisition)

Beyond the preview

Go deeper on Healios.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Healios.

Explore the full profile